Dillon Cockrell, MD

Dad and husband | @DukeGUCancer GU Oncologist, DCI Center for Prostate and Urologic Cancers | Former @UNC Hem/Onc Chief Fellow | @vtcsom grad | Phase 1 trials

[Dillon Cockrell, MD @DCockrellMD]

I recently spoke at the @KidneyCancer Association Duke/UNC patient event on #RCC treatment.

We covered:
• Adjuvant pembro for higher-risk pts
• IO/TKI and dual IO strategies
• How we personalize treatment
• Role of clinical trials

📽️ Full talk: https://t.co/GEEr1WBYwg

[Katy Beckermann @katy_beckermann]

JNJ-6143, first-in-class oral AR-BRD4 RIPTAC, phase 1 mCRPC: a wide window between efficacy and safety. n=105, doses 12.5 to 150 mg.

📈 50 mg daily: PSA50 77%, PSA90 48%, confirmed ORR 69%, after a median 4 prior lines
📊 PSA declines seen from 12.5 to 150 mg. 66% of all patients still on drug
🔍 At 50 mg: 58% any-grade TRAEs, no serious TRAEs. Median DOR 11.0 months, CI 5.9 to NE

Activity across a 12-fold dose range. Phase 2 is open at 50 mg.

Congrats to @BGarmezy on the presentation and all the investigators.

#ESMO26 #ProstateCancer #mCRPC #GUonc

[Dillon Cockrell, MD @DCockrellMD]

Great to see this data presented by @BGarmezy. Excited for this new potential treatment for men with #prostatecancer and to be part of the efforts at @DukeCancer. Appreciate your hard work and leadership @OncHahn!

#ESMO26 @AarmstrongDuke @OncoAlert @myESMO @oncodaily @OncoDailyGU @urotoday

[Andy Hahn @OncHahn]

Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential!

[OncoDaily GU @OncoDailyGU]

10 Must-Read Posts in GU Oncology This Week | October 12–18

This week’s GU oncology selection covers prostate cancer, bladder cancer, RCC, precision imaging, molecular biomarkers, and emerging treatment strategies.

Highlights include:

• Bone health agents and skeletal events in mCRPC
• Phase 2 ZZ-FIRST: talazoparib + enzalutamide
• Gemcitabine + docetaxel in BCG-unresponsive NMIBC • Urinary DNA methylation in low-grade bladder cancer
• PANDORA: PSMA PET/MRI in PI-RADS 3 lesions
• Atezolizumab + prostate SBRT: safety concerns and tumor control findings
• Metformin + ADT in prostate cancer
• Neoadjuvant SAbR in RCC with IVC tumor thrombus
• VOLGA and KEYNOTE-B15 ctDNA at ESMO 2026
• Perioperative immunotherapy in cisplatin-eligible MIBC

@Adam_Weiner535 @MARCANDREANGLES @RomDiamand @seanmmcbride @Raquib_Hannan @DCockrellMD @drenriquegrande

Read the full article - https://t.co/LuHvdPybrl

#OncoDaily #GUOncology

[Dillon Cockrell, MD @DCockrellMD]

@OncHahn @PCFnews Congrats @OncHahn and team. I think before long we will better understand what role GLP-1s can play in men receiving ADT to complement structured lifestyle interventions. Data generated here is a start as we move into RCTs.

[OncoDaily GU @OncoDailyGU]

ESMO26 is Approaching With Several Key GU Studies Being Presented Next Week - Dillon Cockrell

@DCockrellMD

https://t.co/00K6taA7oM

[Dillon Cockrell, MD @DCockrellMD]

4/4 Lastly, a personal connection at #ESMO26 in #ProstateCancer.

🧬 #JNJ6143, formerly #HLD0915 — 2216O
- Updated data for a novel treatment mechanism with an oral AR-targeted #RIPTAC in mAPMR (mCRPC), including patients with high-risk molecular features.
- Looking forward to presentation by @BGarmezy with data on durable activity and tolerability at the selected dose in ARPI-resistant, heavily pretreated disease.

Glad to contribute to this phase I/II work as a co-author and site PI at Duke.

@DukeCancer @OncHahn @AarmstrongDuke @myESMO @OncoAlert @oncodaily @OncoDailyGU @urotoday @GUOncologyNow @DukeGUCancer

[Dillon Cockrell, MD @DCockrellMD]

1/4 #ESMO26 GU preview: a few studies I’ll be watching next week, starting with #ProstateCancer. 👇

🔵 #DASLHiCaP — LBA4
- Darolutamide + ADT + definitive/salvage RT in very-high-risk localized prostate cancer.
- Can this provide another intensification option with RT? Particularly interested in the salvage population, absolute benefit, and tolerability.

🔵 #PROTEUS substudy — LBA53
- Perioperative apalutamide + ADT + prostatectomy vs surgery alone.
- A better comparison IMO beyond the parent trial’s ADT control. Looking for durable outcomes and whether systemic treatment reduces subsequent salvage therapy.

Also watching #CAPItello281 updated OS and mature #PEACE1 survival.

@myESMO @OncoAlert @oncodaily @OncoDailyGU @urotoday @GUOncologyNow

[Dillon Cockrell, MD @DCockrellMD]

3/4 #KidneyCancer at #ESMO26

🟠 #LITESPARK011 — 3587O, 3595RO
- Belzutifan + lenvatinib improved PFS vs cabo after IO (14.8 vs 10.7 mo; HR 0.70), leading to September FDA approval. Final OS not significant (HR 0.85).
- ESMO adds detailed final and QoL analyses. Looking at prior-treatment subgroups and how benefit balances anemia/hypoxia and TKI toxicity.

🟣 #LITESPARK012 — 3586O
- Adding belzutifan to frontline pembro/len missed PFS/OS endpoints. Full results should clarify efficacy and treatment delivery.
- Better disease control after IO, but unsuccessful frontline intensification.

Where does HIF-2α inhibition add the most value? Also watching #PAPMET2 in papillary RCC.

@myESMO @OncoAlert @oncodaily @OncoDailyGU @urotoday @GUOncologyNow

[Karine Tawagi MD @DrKarineTawagi]

4) RCC:
-LITESPARK012: pembro/lenva +/- belzutifan in 1L mRCC (➖PFS & OS press release)
-LITESPARK011 final analysis + QoL belz/lenva vs cabo in 2L mRCC
-Peri-op pembro + met-directed therapy in oligomet RCC
-PD1/VEGF bispecific Inovescimab in RCC

[Karine Tawagi MD @DrKarineTawagi]

3) PROSTATE:
-ctDNA from TALAPRO3
-QoL from CCTG PR21 Lu-617 vs docetaxel in mCRPC
-Updated OS from CAPITELLO281
-LBA ADT + daro in very high risk localized PCa
-PROTAC JNJ-6143 in mCRPC

[Karine Tawagi MD @DrKarineTawagi]

Highlighting upcoming #ESMO26 GU schedule in Madrid 📆 & looking forward to:

1) BLADDER:
-TROPHY-U01 SG + EV/ZIM in 1L mUC
-ctDNA from EV304
-LBA VOLGA: peri-op durva/EV +/- treme (➕ press release for EFS & OS)

2) RARE GU:
-NAT toripalimab in penile CA
-Claudin-6 ADC in GCT

[Andy Hahn @OncHahn]

Very exciting to see Dr. Kat Kayser-Bricker present about the AR-BRD4 RIPTAC, JNJ-6143. A novel MOA with prelim safety and efficacy moving into late phase trials now

[OncoDaily GU @OncoDailyGU]

Patient-Centered Care Remains Central to the Future of Prostate Cancer Treatment - Dillon Cockrell

@DCockrellMD

https://t.co/l42RoQVBQ1

[Dillon Cockrell, MD @DCockrellMD]

Enjoyed joining our @DukeGUCancer team at the @DukeCancer GU Community Education Event to discuss advances in #ProstateCancer care with experts in urology, medical oncology, and radiation oncology, now featured in our Duke #GUrus Fall 2026 newsletter.

Our patient-centered discussion focused on personalized prostate cancer management in the modern era: using biomarkers, genetics, imaging and patient goals to individualize treatment. For patients, understanding their options (which are often many!) boosts confidence in the treatment plan and their team.

Our work expanding early-phase clinical trial access at @DukeRaleigh Cancer Center is also highlighted.

Summary: https://t.co/c2cfwkgtU2
Audio: https://t.co/fXPvQsZZWX

[Dillon Cockrell, MD @DCockrellMD]

Great morning kicking off our @DukeGUCancer #GUrus Community Education Event with a great turnout of patients, colleagues, and industry partners. Looking forward to joining the #ProstateCancer Lunch & Learn with @AarmstrongDuke, @hannahdzmd, Dr. Jeff Gahan, and Dr. Paul Koffer for a patient level discussion on the recent updates in the field.

@DukeHealth @DukeCancer @Daniel_J_George @MSuperdock @MRHarrisonMD @MattLabsMD

[OncoDaily @oncodaily]

Day 1 of VIRO2026 is officially complete! 🧡

A full day of global perspectives, scientific exchange, and discussion on the future of kidney cancer care.

Thank you to all our speakers, moderators and participants.

https://t.co/Q7iwnVX4Wo

[Dillon Cockrell, MD @DCockrellMD]

Great to join today's closing session of #VIRO2026 and discuss case-based decision-making in #RCC.

We covered 3 cases requiring nuranced systemic therapy decision-making:
➡️Adjuvant therapy for high-risk localized ccRCC in light of LITESPARK-022
➡️Aggressive, symptomatic metastatic ccRCC with bone involvement
➡️ High volume, asymptomatic metastatic nodal ccRCC with sarcomatoid histology

Thanks @oncodaily and @OncoDailyGU for the chance to contribute alongside an excellent group of speakers.

[OncoDaily @oncodaily]

📌 VIRO 2026 – Global Voices in Renal Oncology | Closing Session

The closing session of VIRO 2026 – Global Voices in Renal Oncology brought the meeting to a strong conclusion with a practical and forward-looking discussion on the evolving management of renal cell carcinoma, spanning complex surgical presentations, high-risk disease, molecular testing, social determinants of care, and frontline treatment strategies.

Daniel V. Araujo opened the session with a practical discussion on treating clear cell RCC with vena cava thrombus, addressing the complexities of managing this challenging clinical presentation.

Dillon Cockrell explored case-based decision-making in RCC, focusing on treatment approaches for high-risk localized disease and first-line metastatic RCC.

The session then turned to emerging biomarkers, with Arnab Basu examining the current evidence and future directions for ctDNA in RCC. Samuel L. Washington III highlighted the social factors influencing the management of small renal masses, bringing attention to the broader factors that shape clinical decision-making and patient care.

Finally, Fernando Maciel Barbosa, MD discussed frontline RCC treatment in 2026, comparing IO/TKI combinations, dual IO approaches, and emerging triplet strategies as the treatment landscape continues to evolve.

Together, the session highlighted the complexity of modern renal oncology and the importance of integrating clinical expertise, molecular insights, patient-level factors, and emerging therapeutic strategies to advance personalized RCC care.

@DVAraujoMD @DCockrellMD @arnabguonc

🔴 Live sessions available here: https://t.co/OhUe7WxEZZ

🔗 Learn more about VIRO 2026 – Global Voices in Renal Oncology: https://t.co/wA5rN0VDsZ

[Dillon Cockrell, MD @DCockrellMD]

Join me today at #VIRO2026 – Global Voices in Renal Oncology.

I’ll be speaking from 12:35–12:55 PM ET on a case-based approach to high-risk localized and first-line metastatic RCC—from adjuvant pembrolizumab ± belzutifan to selecting among IO/TKI and dual-immunotherapy regimens.

We'll focus on how disease presentation, aggressiveness, and patient preferences should shape treatment decisions.

Tune in live through the @oncodaily link below. Looking forward to joining colleagues from around the world for the discussion.

@OncoDailyGU @DukeGUCancer @DukeCancer @Daniel_J_George @AarmstrongDuke @MRHarrisonMD @KidneyCancer #KidneyCancer #GUOncology #RCC #RenalOncology

[OncoDaily @oncodaily]

VIRO 2026 – Global Voices in Renal Oncology https://t.co/FFByT7Z1NP